Summary
The growth hormone (GH) response to baclofen, a specific GABAB agonist, was tested in 8 male depressed patients before and after chronic treatment with amitriptyline (100mg/day). No difference was seen in plasma GH response before and 28 days after amitriptyline treatment, suggesting that chronic antidepressant drug treatment does not increase hypothalamic GABAB receptor sites in humans. These data suggest that further studies need to support the hypothesis of a GABA involvement in the mechanism of action of antidepressant drugs.
This is a preview of subscription content, log in via an institution to check access.
References
Bartholini G, Lloyd KG, Scatton B, Zivkovic B, Morselli PL (1985) The GABA hypothesis of depression and antidepressant drug action. Psychopharmacol Bull 21: 385–388
Garver DL, Zemlan FP (1986) Receptor studies in diagnosis and treatment of depression. In: Rush AJ, Altshuler KZ (eds) Depression: basic mechanisms, diagnosis, and treatment. The Guilford Press, New York, pp 143–170
Gehlert DR, Yamamura HI, Wamsley JK (1985) Gamma-aminobutyric acid B receptors in the rat brain: quantitative autoradiographic localization using3H(−)baclofen. Neurosci Lett S 6: 183–188
Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56–62
Heninger GR, Charney DS, Sternberg DE (1984) Serotonergic function in depression. Arch Gen Psychiatry 41: 398–402
Johnson DAW (1981) Drug-induced psychiatric disorders. Drugs 22: 57–69
Koulu M, Lammintausta R, Dahlstrom S (1979) Stimulatory effect of acute baclofen administration on human growth hormone and prolactin secretion in man. J Clin Endocrinol Metab 48: 1038–1040
Lerer B (1988) Neurochemical and other neurobiological consequences of ECT: implications for the pathogenesis and treatment of affective disorders. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 577–588
Lloyd KG, Morselli PL, Depoortere H, Fournier V, Zivkovic B, Scatton B, Broekkamp CL, Worms P, Bartholini G (1983) The potential use of GABA agonists in psychiatric disorders: evidence from studies with progabide in animal models and clinical trials. Pharmacol Biochem Behav 18: 957–966
Lloyd KG, Thuret F, Pilc A (1986) GABA and the mechanisms of action of antidepressant drugs. In: Bartholini G, Lloyd KG, Morselli PL (eds) GABA and mood disorders. Raven Press, New York, pp 33–42
Lloyd KG, Morselli PL (1987) Psychopharmacology of GABAergic drugs. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 183–195
Monteleone P, Maj M, Iovino M, Forziati D, Veltro F, Steardo L (1988a) Baclofen-induced growth hormone secretion is blunted in chronic schizophrenics: neuroendocrine evidence for a GABA disturbance in schizophrenia. Psychiatry Res 26: 1–9
Monteleone P, Maj M, Iovino M, Steardo L (1988b) Evidence for a sex difference in the basal growth hormone response to GABAergic stimulation in humans. Acta Endocrinol (Copenh) 119: 353–358
Musch B (1986) Antidepressant activity of fengabine (SL 79229): a critical overview of the present results in open clinical studies. In: Bartholini G, Lloyd KG, Morselli PL (eds) GABA and mood disorders. Raven Press, New York, pp 171–177
Naik SR, Guidotti A, Costa A (1976) Central GABA receptor agonists: comparison of muscimol and baclofen. Neuropharmacology 15: 479–484
Passariello N, Giugliano D, Torella R, Sgambato S, Coppola L, Frascolla N (1982) A possible role for gamma-aminobutyric acid in the control of endocrine pancreas secretion. J Clin Endocrinol Metab 54: 1145–1149
Pilc A, Lloyd KG (1984) Chronic antidepressants and GABA “B” receptors: a GABA hypothesis of antidepressant drug action. Life Sci 35: 2149–2154
Sanger DJ, Joly D, Depoortere H, Zivkovic B, Lloyd KG (1986) Behavioral profile of progabide in tests for anxiolytics and antidepressant drugs. In: Bartholini G, Lloyd KG, Morselli PL (eds) GABA and mood disorders. Raven Press, New York, pp 77–84
Scatton B, Lloyd GK, Zivkovic B, Dennis T, Claustre Y, Dedek J, Arbilla S, Langer SZ, Bartholini G (1987) Fengabine, a novel antidepressant GABAergic agent. II. Effect on cerebral noradrenergic, serotonergic and GABAergic transmission in the rat. J Pharmacol Exp Ther 241: 251–257
Stryker TD, Conlin T, Reichlin S (1986) Influence of a benzodiazepine, midazolam, and gamma-aminobutyric acid (GABA) on basal somatostatin secretion from cerebral and diencephalic neurons in dispersed cell cultures. Brain Res 362: 339–343
Takahara J, Yunoki S, Osogi K, Yakushiji W, Kageyama J, Ofuji T (1980) Concomitant increases in serum growth hormone and hypothalamic somatostatin in rats after injection of gamma-aminobutyric acid, aminooxyacetic acid or gamma-hydroxybutyric acid. Endocrinology 106: 343–347
Willoughby JO, Jervois PM, Menadue MF, Blessing WN (1986) Activation of GABA receptors in the hypothalamus stimulates secretion of growth hormone and prolactin. Brain Res 374: 119–124
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Monteleone, P., Steardo, L., Tanzillo, C. et al. Chronic antidepressant drug treatment does not affect GH response to baclofen in depressed subjects. J. Neural Transmission 82, 147–152 (1990). https://doi.org/10.1007/BF01245171
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01245171